DDInter1022 DDInter1435
Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Lansoprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Lansoprazole {u} (Compound) binds {v} (Gene) ATP4A
Lansoprazole {u} (Compound) upregulates {v} (Gene) ZNF274
Lansoprazole {u} (Compound) is included by {v} (Pharmacologic Class) Inhibition Gastric Acid Secretion
Lansoprazole {u} (Compound) downregulates {v} (Gene) PRKACA
Lansoprazole {u} (Compound) causes {v} (Side Effect) Laboratory test abnormal
Lansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Axitinib
Lansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyanocobalamin
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capreomycin
Lansoprazole (Compound) resembles Rabeprazole (Compound)
Lansoprazole (Compound) binds ATP4A (Gene)
Lansoprazole (Compound) upregulates ZNF274 (Gene)
Lansoprazole (Compound) is included by Inhibition Gastric Acid Secretion (Pharmacologic Class)
Lansoprazole (Compound) downregulates PRKACA (Gene)
Lansoprazole (Compound) causes Laboratory test abnormal (Side Effect)
Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib
Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Cyanocobalamin
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Capreomycin